VEGF Injection Therapeutic Methods for Treatment of Age-Related MacularDegeneration (AMD): A Comparison and new study

As the population around the world ages, more and more people are at risk of chronic eye diseases, aging processes, and eye and systemic co-morbidities. Age-related macular degeneration (AMD), which is non-exudative or ‘‘dry’’ in early stages and may convert to exudative or ‘‘wet’’ in later stages (neovascular AMD, nAMD), is characterized by progressive loss of central vision that can become severe.Neovascular AMD (nAMD), also known as wet or exudative AMD is characterized by the growth of new, abnormal vasculature from the choriocapillaris extending into the retina, threatening the photoreceptors or retinal pigment epithelium (RPE). Exudation, fluid accumulation and hemorrhages from the vessels can result in vision loss, via RPE detachment or subretinal fibrosis if not promptly treated.This disease is mostly untreatable and only controllable. Since the main cause of this illness is the abnormal growth of vasculature of the retina, it is controlled by stopping the growth. In other words, controlling the growth by injecting Anti-VEGF into the eyeball. By injecting the anti-VEGF factors into the retina area, the vasculature growth stops for a while and help the patient to have a better sight.

کلیدواژه ها:

AMD ، Bevacizumab ، Aflibercept ، Nanocarriers ، Hydrogels